Dazodalibep
VIB4920 / HZN-4920Non-antibody CD40L-binding agent with engineered platelet safety. Three concurrent P3s in Sjogren's — n=434, n=651, n=844.
Target: CD40LG CD40L-binding non-antibody fusion protein (avoids Fc-mediated platelet activation) Amgen Inflammation
When will we know if it works?
Fresh est.A positive readout makes CD40LG a validated target for the first time. Hover the badge above for what the confidence level means.
3
Phase 3 trials
3 active · 0 completed
3
Total trials
P2: 0 · P1: 0
844
Max trial size
across 3 indications
1
Sponsors at target
incl. 2 other assets
What does it do?
CD40LG — CD40 ligand (CD154)
Modality: CD40L-binding non-antibody fusion protein (avoids Fc-mediated platelet activation)
The 3 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT06104124 | Sjogren's Syndrome | 651 | ACTIVE_NOT_RECRUITING | 2024-01-24 | 2026-08-19 | Fresh est. |
| NCT06245408 | Sjögren's Syndrome (SS) | 434 | ACTIVE_NOT_RECRUITING | 2024-04-08 | 2026-10-22 | Fresh est. |
| NCT06747949 | Sjögren's Syndrome | 844 | RECRUITING | 2025-02-25 | 2029-12-11 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2023 | acquisition | Horizon Therapeutics | $28B (Horizon acquisition by Amgen) |
| 2021 | acquisition | Viela Bio (originator) | $3B (Horizon acquisition of Viela) |
What's the case for and against?
✓ What's working in its favor
- Phase 2 Sjogren's positive (improvement in ESSDAI and CRESS composite endpoint)
- Distinct mechanism from frexalimab (no Fc region, smaller MW)
Who else is racing? — 2 other assets at CD40LG
| Asset | Sponsor | Status |
|---|---|---|
| Frexalimab | Sanofi | P3 MS, P2 T1D/FSGS |
| Iscalimab (CFZ533) | Novartis | P2 — anti-CD40 not anti-CD40L |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.